霍奇金淋巴瘤中E病变的意义及新共识定义的建立:SEARCH的报告
SEARCH工作组通过文献检索纳入36篇描述12640例患者的文章,评估霍奇金淋巴瘤中E病变的定义与预后意义。I-III期患者E病变总发生率为11.5%(1330/11602例),II期与III期发生率相似(21.2% vs 21.9%),I期罕见(1.1%)。基于证据与共识形成统一的E病变定义,推荐在未來临床试验中应用并明确报告以确认其预后价值。
要点
- I-III期霍奇金淋巴瘤E病变总发生率为11.5%(1330/11602例)。
- II期与III期E病变发生率相似(21.2% vs 21.9%),I期罕见(1.1%)。
- 基于证据与SEARCH工作组共识形成统一的E病变定义,推荐在未來临床试验中应用并明确报告。
核心结论
- E病变可能仍具预测价值,但在更选择性使用靶向放疗的现代时代,不能明确断定识别E病变可提供预后价值。
- 推荐在未來临床试验中应用该E病变定义并明确报告,以确认E病变的预后价值。
研究设计与样本
- SEARCH for CAYAHL工作组通过PubMed和Google Scholar数据库进行文献检索,检索词包括「Hodgkin disease」及「extranodal」「extralymphatic」「E lesions」「E stage」或「E disease」。
- 共36篇文章描述12640例患者符合纳入标准,审查内容包括参与者数量、中位年龄与年龄范围、分期诊断方法以及E病变的定义、发生率和预后意义。
主要发现
- 大多数文章按Ann Arbor分期(72%,26/36)或Cotswolds修改的Ann Arbor分期标准(25%,9/36)报告分期,文章很少定义E病变或区分「结外疾病」。
- I-III期霍奇金淋巴瘤患者E病变总体发生率为11.5%(1330/11602例唯一患者)。
- 对3888例患者的可用分期特异性发生率分析显示,II期E病变发生率为21.2%,III期为21.9%,I期罕见为1.1%。
关键数值与推荐
- 基于现有证据和SEARCH工作组共识达成统一的E病变定义。
- 推荐在未來临床试验中应用该E病变定义并明确报告,以确认E病变的预后价值。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 文章很少定义E病变或区分「结外疾病」。
- 不能明确断定识别E病变在现代更选择性使用靶向放疗的时代具有预后价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The International Staging Evaluation and Response Criteria Harmonization for Childhood, Adolescent, and Young Adult Hodgkin Lymphoma (SEARCH for CAYAHL) seeks to provide an appropriate, universal differentiation between E-lesions and stage IV extranodal disease in Hodgkin lymphoma (HL). A literature search was performed through the PubMed and Google Scholar databases using the terms "Hodgkin disease," and "extranodal," "extralymphatic," "E lesions," "E stage," or "E disease." Publications were reviewed for the number of participants; median age and age range; diagnostic modalities used for staging; and the definition, incidence, and prognostic significance of E-lesions. Thirty-six articles describing 12 640 patients met the inclusion criteria. Most articles reported staging per the Ann Arbor (72%, 26/36) or Cotswolds modification of the Ann Arbor staging criteria (25%, 9/36), and articles rarely defined E-lesions or disambiguated "extranodal disease." The overall incidence of E-lesions for patients with stage I-III HL was 11.5% (1330/11 602 unique patients). Available stage-specific incidence analysis of 3888 patients showed a similar incidence of E-lesions in stage II (21.2%) and stage III (21.9%), with E-lesions rarely seen with stage I disease (1.1%). E-lesions likely remain predictive, but we cannot unequivocally conclude that identifying E-lesions in HL imparts prognostic value in the modern era of the more selective use of targeted radiation therapy. A harmonized E-lesion definition was reached based on the available evidence and the consensus of the SEARCH working group. We recommend that this definition of E-lesion be applied in future clinical trials with explicit reporting to confirm the prognostic value of E-lesions.
引用
- Zijtregtop EAM, Zeal J, Metzger ML, et al. Significance of E-lesions in Hodgkin lymphoma and the creation of a new consensus definition: a report from SEARCH. Blood Adv. 2023. PMID: 37522740. doi:10.1182/bloodadvances.2023010024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。